Patents by Inventor Andrew Camilli
Andrew Camilli has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10953053Abstract: Compositions and methods are provided for preventing, ameliorating, or treating a disease caused by a species of bacterial genus Vibrio, for example, cholera caused by V. cholerae, the compositions containing two or more strains of lytic bacteriophage that infect and kill Vibrio cells. The bacteriophage are virulent, which replicate intracellularly and lyse and kill the bacteria. Use of two or more strains in a single treatment, as a result of a rate of mutation of the bacteria to simultaneous resistance to all of the bacteriophage to be so low as to be negligible, reduces appearance of phage-resistant bacteria to statistical negligibility. Normal human microbial flora species were not affected. In alternative embodiments of the method and the composition, antibiotic agents or other treatment agents can be administered with a cocktail of the plurality of bacteriophage strains.Type: GrantFiled: September 28, 2018Date of Patent: March 23, 2021Assignee: TRUSTEES OF TUFTS COLLEGEInventors: Andrew Camilli, Lynne Cairns, Minmin Yen
-
Publication number: 20190099459Abstract: Compositions and methods are provided for preventing, ameliorating, or treating a disease caused by a species of bacterial genus Vibrio, for example, cholera caused by V. cholerae, the compositions containing two or more strains of lytic bacteriophage that infect and kill Vibrio cells. The bacteriophage are virulent, which replicate intracellularly and lyse and kill the bacteria. Use of two or more strains in a single treatment, as a result of a rate of mutation of the bacteria to simultaneous resistance to all of the bacteriophage to be so low as to be negligible, reduces appearance of phage-resistant bacteria to statistical negligibility. Normal human microbial flora species were not affected. In alternative embodiments of the method and the composition, antibiotic agents or other treatment agents can be administered with a cocktail of the plurality of bacteriophage strains.Type: ApplicationFiled: September 28, 2018Publication date: April 4, 2019Applicant: Trustees of Tufts CollegeInventors: Andrew Camilli, Lynne Cairns, Minmin Yen
-
Patent number: 9914950Abstract: According to some aspects of the invention, provided herein are methods of amplifying nucleic acids using homopolymer-mediated ligation. The methods, in some embodiments, comprise adding a first homopolymer of at least 12 nucleotides to each 3? end of blunt-ended double-stranded nucleic acid containing a target nucleic acid, thereby producing a partially double-stranded nucleic acid.Type: GrantFiled: August 23, 2013Date of Patent: March 13, 2018Assignee: Tufts UniversityInventors: David W. Lazinski, Andrew Camilli
-
Publication number: 20170051311Abstract: The present invention includes compositions and methods of co-transformation of naturally competent cells. In one aspect of the invention, a method is included for introducing nucleic acid sequences into one or more naturally competent cells in parallel. In other aspects, a heterogenic pool of co-transformed naturally competent cells and an apparatus for introducing two or more populations of nucleic acid sequences into a population of naturally competent cells in parallel are also included.Type: ApplicationFiled: May 1, 2015Publication date: February 23, 2017Applicant: TUFTS UNIVERSITYInventors: ANKUR B. DALIA, ANDREW CAMILLI
-
Publication number: 20150203887Abstract: According to some aspects of the invention, provided herein are methods of amplifying nucleic acids using homopolymer-dedicated ligation. The methods, in some embodiments, comprise adding a first homopolymer of at least 12 nucleotides to each 3? end of blunt-ended double-stranded nucleic acid containing a target nucleic acid, thereby producing a partially double-stranded nucleic acid.Type: ApplicationFiled: August 23, 2013Publication date: July 23, 2015Applicant: Tufts UniversityInventors: David W. Lazinski, Andrew Camilli
-
Patent number: 8642046Abstract: The methods and compositions of the present invention are directed to a vaccine against Vibrio cholerae comprised of V. cholerae outer membrane vesicles (OMVs). Such vaccines are relatively stable, facilitating distribution. Inventive methods generally include administration of a vaccine against Vibrio cholerae by intranasal, intraperitoneal, oral or intragastric routes. Such vaccines confer immunity to the individual, and when administered to pregnant subjects, can be conferred to the offspring of individuals.Type: GrantFiled: October 9, 2008Date of Patent: February 4, 2014Assignee: Tufts UniversityInventors: Andrew Camilli, Stefan Schild, Eric Jorge Nelson
-
Publication number: 20100247566Abstract: The methods and compositions of the present invention are directed to a vaccine against Vibrio cholerae comprised of V. cholerae outer membrane vesicles (OMVs). Such vaccines are relatively stable, facilitating distribution. Inventive methods generally include administration of a vaccine against Vibrio cholerae by intranasal, intraperitoneal, oral or intragastric routes. Such vaccines confer immunity to the individual, and when administered to pregnant subjects, can be conferred to the offspring of individuals.Type: ApplicationFiled: October 9, 2008Publication date: September 30, 2010Applicant: TUFTS UNIVERSITYInventors: Andrew Camilli, Stefan Schild, Eric Jorge Nelson
-
Patent number: 6207384Abstract: The invention features a general system for the identification of essential genes in organisms. This system is applicable to the discovery of novel target genes for antimicrobial compounds, as well as to the discovery of genes that enhance cell growth or viability.Type: GrantFiled: March 26, 1999Date of Patent: March 27, 2001Assignees: The General Hospital Corporation, Trustees of Tufts College, President and Fellows of Harvard CollegeInventors: John J. Mekalanos, Brian J. Akerley, Eric J. Rubin, Andrew Camilli
-
Vibrio cholerae mutants which are soft-agar penetration defective and lack a functional CtxA subunit
Patent number: 6203799Abstract: V. cholerae vaccine strains which have a soft agar penetration-defective phenotype and methods for making such strains are described. Also described are methods for identifying new genes involved in V. cholerae motility and the cloning, identification, and sequencing of V. cholerae motB and fliC genes.Type: GrantFiled: December 2, 1994Date of Patent: March 20, 2001Assignee: Presidents and Fellows of Harvard CollegeInventors: John J. Mekalanos, Claudette L. Gardel, Andrew Camilli -
Patent number: 5571688Abstract: A reporter system relating to in vivo expression technology was devised to aid in the identification and study of genes that display temporal or spatial patterns of expression during infection of host tissues. The method of this invention comprises constructing a strain or pool of strains of a microorganism which contains an artificial cointegrate comprising a reporter gene flanked by direct repeats of sequences to which a resolvase enzyme binds, thus catalyzing excision of the reporter gene, and further contains a coding sequence under the control of a promoter sequence which encodes transcripts, the expression of which are easily monitored in vitro and which result in a permanent genetic change, excision of the reporter gene, that is heritable and easily detectable subsequent to induction of the synthetic operon.Type: GrantFiled: February 27, 1995Date of Patent: November 5, 1996Inventors: John J. Mekalanos, Andrew Camilli
-
Patent number: 5512452Abstract: A reporter system relating to in vivo expression technology was devised to aid in the identification and study of genes that display temporal or spatial patterns of expression during infection of host tissues. The method of this invention comprises integrating a site-specific DNA recombinase expression vector, and a reporter gene that is permanently removable by the recombinase, by way of homologous recombination into a microorganism's chromosome and inducing the expression of a synthetic operon which encodes transcripts, the expression of which are easily monitored in vitro and which result in a permanent genetic change, excision of the reporter gene, that is heritable and easily detectable subsequent to induction of the synthetic operon.Type: GrantFiled: September 28, 1993Date of Patent: April 30, 1996Assignee: President and Fellows of Harvard CollegeInventors: John J. Mekalanos, Andrew Camilli